title: [Equalization of breast cancer chemotherapy at general hospital( II )-evaluation of safety in FEC and TC regimens].
abstract: The safety of epirubicin (75 mg/m(2)), 5-fluorouracil (500 mg/m(2)) plus cyclophosphamide (500 mg/m(2)) (FEC75 therapy) and docetaxel (75 mg/m(2)) plus cyclophosphamide (600 mg/m(2)) (TC therapy) every three weeks as neoadjuvant or adjuvant chemotherapy was evaluated. Six or 9 patients received FEC75 or TC therapy, respectively. The nadir of white blood cells and neutrocyte counts in FEC75 and TC therapy were after 11-15 days and 8-11 days of chemotherapy, respectively. On the other hand, those of monocyte and reticulocyte counts were after 8-11 and 4-8 days for FEC75 and TC therapy, respectively. This suggests that there is a lag time in these parameters for the evaluation of myelosuppression in each chemotherapy regimen, resulting in the prediction of the degree of myelotoxicity by these profiles. Although 2 patients who received TC therapy encountered febrile neutropenia, the symptoms were improved by quinolones, and so granulocyte colony-stimulating factor was not needed. In addition, remarkable non-hematological side effects were not observed, and, therefore, almost all chemotherapy was performed as scheduled. From these results, FEC75 and TC therapy are considered to be safe.
authors.affiliation: Dept. of Pharmacy, Takarazuka Municipal Hospital.
authors.forename: Noriaki
authors.initials: N
authors.lastname: Kitada
authors.forename: Masayuki
authors.initials: M
authors.lastname: Nishino
authors.forename: Jun
authors.initials: J
authors.lastname: Yasuda
authors.forename: Satoko
authors.initials: S
authors.lastname: Morita
authors.forename: Chika
authors.initials: C
authors.lastname: Fujii
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Minegaki
authors.forename: Mayumi
authors.initials: M
authors.lastname: Kondoh
authors.forename: Setsuko
authors.initials: S
authors.lastname: Anami
authors.forename: Kohji
authors.initials: K
authors.lastname: Takara
authors.forename: Masakatsu
authors.initials: M
authors.lastname: Watari
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D001772:Blood Cell Count; D001943:Breast Neoplasms / Q000188:drug therapy*; D002939:Ciprofloxacin / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000009:adverse effects* / Q000627:therapeutic use; D000077143:Docetaxel; D015251:Epirubicin / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D005472:Fluorouracil / Q000009:adverse effects / Q000627:therapeutic use; D006769:Hospitals, General; D006801:Humans; D007564:Japan; D008875:Middle Aged; D009503:Neutropenia / Q000139:chemically induced* / Q000188:drug therapy; D043823:Taxoids / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D043823:Taxoids; D000077143:Docetaxel; D015251:Epirubicin; D002939:Ciprofloxacin; D003520:Cyclophosphamide; D005472:Fluorouracil